Filing Details

Accession Number:
0001567619-21-019063
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-01 14:20:02
Reporting Period:
2021-10-29
Accepted Time:
2021-11-01 14:20:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921114 Armata Pharmaceuticals Inc. ARMP Biological Products, (No Disgnostic Substances) (2836) 911549568
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1080014 Innoviva, Inc. 1350 Old Bayshore Highway Suite 400
Burlingame CA 94010
Yes No Yes No
1842875 Innoviva Strategic Opportunities Llc 1350 Old Bayshore Highway Suite 400
Burlingame CA 94010
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-29 1,212,122 $3.30 7,365,969 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,710,800 Direct
Footnotes
  1. On October 28, 2021, Innoviva Strategic Opportunities LLC ("Innoviva Sub"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. ("Innoviva" and, together with Innoviva Sub, the "Reporting Persons"), entered into that certain Securities Purchase Agreement (the "Purchase Agreement") with Armata Pharmaceuticals, Inc., a Washington corporation (the "Issuer") and another purchaser, pursuant to which, on October 29, 2021 Innoviva Sub acquired 1,212,122 newly issued shares of common stock, $0.01 par value per share, of the Issuer ("Common Stock"). In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of an additional 6,153,847 shares of Common Stock and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock.
  2. In 2020, Innoviva designated Odysseas Kostas, M.D. and in 2021, Innoviva designated Jules Haimovitz, two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4.